Research and Practice in Thrombosis and Haemostasis最新文献

{"title":"Intensive care treatment in acute pulmonary embolism in Germany, 2016 to 2020: a nationwide inpatient database study","authors":"","doi":"10.1016/j.rpth.2024.102545","DOIUrl":"10.1016/j.rpth.2024.102545","url":null,"abstract":"<div><h3>Background</h3><p>Pulmonary embolism (PE) is a potentially life-threatening condition. Admission and treatment in the intensive care unit (ICU) is an important element in critically ill PE patients.</p></div><div><h3>Objectives</h3><p>We aimed to identify risk factors for ICU admission and differences in patient profiles regarding risk factors and comorbidities between PE patients who had to be admitted to an ICU and those who were treated in a normal ward without ICU.</p></div><div><h3>Methods</h3><p>We used the German nationwide inpatient sample to analyze all hospitalizations of PE patients in Germany from 2016 to 2020 stratified for ICU admission.</p></div><div><h3>Results</h3><p>Overall, 484,859 hospitalized PE patients were treated in German hospitals from 2016 to 2020. Among these, 92,313 (19.0%) were admitted to ICU. Patients treated in ICU were younger (69.0 [IQR, 58.0-78.0] vs 72.0 [IQR, 60.0-80.0] years; <em>P</em> &lt; .001) and had higher prevalence of cardiovascular risk factors and comorbidities. In-hospital case fatality rate was elevated in PE patients treated in ICU (22.7% vs 10.7%; <em>P</em> &lt; .001), and ICU admission was independently associated with increased in-hospital case fatality (odds ratio [OR], 2.54; 95% CI, 2.49-2.59; <em>P</em> &lt; .001). Independent risk factors for ICU admission comprised PE with imminent or present decompensation (OR, 3.30; 95% CI, 3.25-3.35; <em>P</em> &lt; .001), hemodynamic instability (OR, 4.49; 95% CI, 4.39-4.59; <em>P</em> &lt; .001), arterial hypertension (OR, 1.20; 95% CI, 1.18-1.22; <em>P</em> &lt; .001), diabetes mellitus (OR, 1.16; 95% CI, 1.14-1.18; <em>P</em> &lt; .001), obesity (OR, 1.300; 95% CI, 1.27-1.33; <em>P</em> &lt; .001), surgery (OR, 2.55; 95% CI, 2.50-2.59; <em>P</em> &lt; .001), stroke (OR, 2.86; 95% CI, 2.76-2.96; <em>P</em> &lt; .001), pregnancy (OR, 1.45; 95% CI, 1.21-1.74; <em>P</em> &lt; .001), heart failure (OR, 1.74; 95% CI, 1.71-1.77; <em>P</em> &lt; .001), atrial fibrillation/flutter (OR, 1.69; 95% CI, 1.66-1.73; <em>P</em> &lt; .001), chronic obstructive pulmonary disease (OR, 1.21; 95% CI, 1.18-1.24; <em>P</em> &lt; .001), and renal failure (OR, 1.92; 95% CI, 1.88-1.95; <em>P</em> &lt; .001).</p></div><div><h3>Conclusion</h3><p>ICU treatment is an important element in the treatment of PE patients. Besides hemodynamic compromise, cardiovascular risk factors, stroke, pregnancy, and cardiopulmonary as well as renal comorbidities were independent predictors of ICU admission. Necessity of ICU admission was afflicted by increased case fatality.</p></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2475037924002401/pdfft?md5=5fa4f690799b0d60d45ce0b7bd808ed8&pid=1-s2.0-S2475037924002401-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142122798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to undertake procedures while on antiplatelet agents: a hematologist's view","authors":"","doi":"10.1016/j.rpth.2024.102539","DOIUrl":"10.1016/j.rpth.2024.102539","url":null,"abstract":"<div><p>Cardiovascular diseases (CVDs) are the leading cause of mortality globally while also contributing to excess health system costs. Significant advancements have been made in the understanding and prevention of deaths from CVD. In addition to risk factor modifications, one of the key developments in this area is the appropriate prescribing of antiplatelet medications for secondary prevention of CVD. With the advent of vascular devices, there has been an increased use of potent antiplatelet agents to mitigate thrombosis risk. A well-recognized, albeit rare complication of antiplatelet drugs is the heightened risk of bleeding. This adverse effect is particularly relevant when a patient receiving these medications may require an urgent surgery. In addition, for elective surgeries, although these drugs can be withheld, there may be some situations when interruption of antiplatelet agents, even for short duration, may lead to thrombotic events. There are no robust guidelines on how to manage these clinical scenarios, although there have been some important studies published recently in this area. In this review, we provide our approach to patients on antiplatelet drugs who may require urgent surgeries or surgical interventions.</p></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2475037924002346/pdfft?md5=78de6035121dc620f6bf450c75563bb9&pid=1-s2.0-S2475037924002346-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142122796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of diagnostic delays and loss to follow-up in women with von Willebrand disease: a single-center retrospective cohort study","authors":"","doi":"10.1016/j.rpth.2024.102567","DOIUrl":"10.1016/j.rpth.2024.102567","url":null,"abstract":"<div><h3>Background</h3><div>Women with von Willebrand disease (VWD) often face diagnostic delays, leading to increased bleeds, stress, and healthcare use. The factors influencing these delays and their effects on gynecologic outcomes are not well understood.</div></div><div><h3>Objectives</h3><div>This study aimed to 1) identify the prevalence and predictors of diagnostic delays and loss to follow-up in women with VWD and 2) determine how these delays affect severe gynecologic bleeding, emergency visits, transfusions, and hysterectomies.</div></div><div><h3>Methods</h3><div>We conducted a single-center retrospective cohort study and included women aged ≥18 years diagnosed with VWD. Delayed diagnosis was defined as ≥3 bleeding events prior to VWD diagnosis, excluding easy bruising due to its subjectivity. Loss to follow-up was defined as ≥5 years since the last hematology visit. We used logistic regression for analysis.</div></div><div><h3>Results</h3><div>Among 178 diagnosed women (median age, 27 years), 71 (40%) experienced ≥3 bleeding events before diagnosis. The median time from the first bleeding event to VWD diagnosis was 14.2 years. Severe bleeding events significantly predicted diagnostic delays (adjusted odds ratio, 3.1; 95% CI, 1.5-6.2). Fifty-four (30%) women were lost to follow-up, with remote era of initial bleed and VWD type identified as significant predictors. Delays were associated with increased risks of hysterectomies (odds ratio, 2.7; 95% CI, 1.2-6.3) and other gynecologic procedures.</div></div><div><h3>Conclusion</h3><div>Delayed diagnosis and loss to follow-up in VWD are common even in a specialized Hemophilia Treatment Centre. Such delays lead to more severe bleeding and increased gynecologic interventions. Prompt diagnosis is paramount for better patient outcomes and reduced healthcare utilization.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142327446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physician practice patterns on the use of inferior vena cava filters in venous thromboembolism","authors":"","doi":"10.1016/j.rpth.2024.102540","DOIUrl":"10.1016/j.rpth.2024.102540","url":null,"abstract":"","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2475037924002358/pdfft?md5=a64ce17836a7c7ab2096db8f305142a1&pid=1-s2.0-S2475037924002358-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142049526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter in response to Bounaix et al. “Management of anticoagulation and factor XIII replacement in a patient with severe factor XIII deficiency and recurrent venous thromboembolic disease: case report and review of literature”","authors":"","doi":"10.1016/j.rpth.2024.102535","DOIUrl":"10.1016/j.rpth.2024.102535","url":null,"abstract":"","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2475037924002309/pdfft?md5=d3045fb8c25860a06064eb3cc8d32f5a&pid=1-s2.0-S2475037924002309-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142098441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual direct oral anticoagulant therapy in challenging thrombosis: a case series","authors":"","doi":"10.1016/j.rpth.2024.102546","DOIUrl":"10.1016/j.rpth.2024.102546","url":null,"abstract":"<div><h3>Background</h3><p>While anticoagulation therapy is highly effective at treating venous thromboembolism, some patients can develop rapidly progressive thrombosis in multiple organs or sites despite therapeutic anticoagulation. Effective strategies to manage life-threatening thrombosis in these patients are elusive.</p></div><div><h3>Objectives</h3><p>We describe our experience using dual direct oral anticoagulant (DOAC) therapy with a factor (F)Xa inhibitor (such as rivaroxaban or apixaban) and a FIIa inhibitor (dabigatran) for refractory cases of thrombosis.</p></div><div><h3>Methods</h3><p>A retrospective chart review of all patients treated with simultaneous dabigatran and an oral FXa inhibitor at our institution was conducted. We included all patients over the age of 18. The study was approved by the University of British Columbia Research Ethics Board (REB number: H23-02575).</p></div><div><h3>Results</h3><p>Eight patients were included. All patients initiated standard therapeutic anticoagulation upon diagnosis of acute venous thromboembolism with a median of 3 breakthrough thrombotic events prior to dual DOAC use. Five patients had a positive heparin-induced thrombocytopenia screen, but only 2 had heparin-induced thrombocytopenia confirmed on serotonin release assay testing. There were no recurrent deep vein thrombosis, pulmonary embolism, or bleeding events during dual DOAC use. Most patients ultimately transitioned to a single oral FXa inhibitor.</p></div><div><h3>Conclusion</h3><p>Dual DOAC therapy may be a useful strategy for managing challenging thrombosis cases resistant to conventional anticoagulation. Further research is warranted to validate these findings and explore the broader applicability of dual DOAC therapy in challenging thrombotic scenarios.</p></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2475037924002413/pdfft?md5=816305b13c2dbee16632497e0e5e5dd9&pid=1-s2.0-S2475037924002413-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142151132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antipolyphosphate monoclonal antibodies derived from autoimmune mice","authors":"","doi":"10.1016/j.rpth.2024.102550","DOIUrl":"10.1016/j.rpth.2024.102550","url":null,"abstract":"<div><h3>Background</h3><p>Inorganic polyphosphates (polyPs) are linear chains of phosphates that accelerate blood clotting. Targeting polyP <em>in vivo</em> has been shown to reduce thrombosis.</p></div><div><h3>Objectives</h3><p>To identify and characterize anti-polyP monoclonal antibodies that could be used as analytical tools and as antithrombotic agents.</p></div><div><h3>Methods</h3><p>Hybridomas were prepared from spleen cells from autoimmune NZBWF1/J female mice and screened for anti-polyP antibodies. Antibodies that bound polyP using enzyme-linked immunosorbent assay and pull-down assays were further characterized with plate binding, surface plasmon resonance, and plasma-based clotting assays. Antithrombotic potential was evaluated in a murine ferric chloride–induced carotid artery thrombosis model.</p></div><div><h3>Results</h3><p>Of 4 antibodies that bound polyP in our pull-down assay, 2 (PP2069 and PP2099) were available for further characterization. While analyzing these anti-polyP antibodies, we found secretory leukocyte peptidase inhibitor (SLPI) to be a common contaminant of these antibodies and that SLPI binds polyP. We removed SLPI quantitatively from our purified immunoglobulin G. Both PP2069 and PP2099 immunoglobulin G displayed high affinity for polyP but also bound to other polyanions such as DNA, heparin, and certain other glycosaminoglycans, indicating limited specificity. Both antibodies inhibited polyP-initiated plasma clotting <em>in vitro</em>. When tested <em>in vivo</em> in a mouse thrombosis model, however, neither PP2069 nor PP2099 exhibited a significant antithrombotic effect.</p></div><div><h3>Conclusion</h3><p>Autoimmune mice spontaneously produce antibodies against polyP. The 2 examples of anti-polyP monoclonal antibodies studied here not only bound to polyP with high affinity but also cross-reacted with DNA and heparin. Neither antibody protected against thrombosis in a mouse model, but they might have some utility for <em>in vitro</em> studies of polyP.</p></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2475037924002450/pdfft?md5=f196d103a0baf733ec746abc85e4c216&pid=1-s2.0-S2475037924002450-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142161862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MYH9-related inherited thrombocytopenia: the genetic spectrum, underlying mechanisms, clinical phenotypes, diagnosis, and management approaches","authors":"","doi":"10.1016/j.rpth.2024.102552","DOIUrl":"10.1016/j.rpth.2024.102552","url":null,"abstract":"<div><p>Inherited thrombocytopenias have been considered exceedingly rare for a long time, but recent advances have facilitated diagnosis and greatly enabled the discovery of new causative genes. <em>MYH9</em>-related disease (<em>MYH9-</em>RD) represents one of the most frequent forms of inherited thrombocytopenia, usually presenting with nonspecific clinical manifestations, which renders it difficult to establish an accurate diagnosis. <em>MYH9-</em>RD is an autosomal dominant-inherited thrombocytopenia caused by deleterious variants in the <em>MYH9</em> gene encoding the heavy chain of nonmuscle myosin IIA. Patients with <em>MYH9</em>-RD usually present with thrombocytopenia and platelet macrocytosis at birth or in infancy, and most of them may develop one or more extrahematologic manifestations of progressive nephritis, sensorial hearing loss, presenile cataracts, and elevated liver enzymatic levels during childhood and adult life. Here, we have reviewed recent advances in the study of <em>MYH9</em>-RD, which aims to provide an updated and comprehensive summary of the current knowledge and improve our understanding of the genetic spectrum, underlying mechanisms, clinical phenotypes, diagnosis, and management approaches of this rare disease. Importantly, our goal is to enable physicians to better understand this rare disease and highlight the critical role of genetic etiologic analysis in ensuring accurate diagnosis, clinical management, and genetic counseling while avoiding ineffective and potentially harmful therapies for <em>MYH9</em>-RD patients.</p></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2475037924002474/pdfft?md5=25f8cdaec23ba07ea71ddb4dc9a6f91c&pid=1-s2.0-S2475037924002474-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142161861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oxidative stress–induced fibrinogen modifications in liver transplant recipients: unraveling a novel potential mechanism for cardiovascular risk","authors":"","doi":"10.1016/j.rpth.2024.102555","DOIUrl":"10.1016/j.rpth.2024.102555","url":null,"abstract":"<div><h3>Background</h3><p>Cardiovascular events represent a major cause of non–graft-related death after liver transplant. Evidence suggest that chronic inflammation associated with a remarkable oxidative stress in the presence of endothelial dysfunction and procoagulant environment plays a major role in the promotion of thrombosis. However, the underlying molecular mechanisms are not completely understood.</p></div><div><h3>Objectives</h3><p>In order to elucidate the mechanisms of posttransplant thrombosis, the aim of the present study was to investigate the role of oxidation-induced structural and functional fibrinogen modifications in liver transplant recipients.</p></div><div><h3>Methods</h3><p>A case-control study was conducted on 40 clinically stable liver transplant recipients and 40 age-matched, sex-matched, and risk factor–matched controls. Leukocyte reactive oxygen species (ROS) production, lipid peroxidation, glutathione content, plasma antioxidant capacity, fibrinogen oxidation, and fibrinogen structural and functional features were compared between patients and controls.</p></div><div><h3>Results</h3><p>Patients displayed enhanced leukocyte ROS production and an increased plasma lipid peroxidation with a reduced total antioxidant capacity compared with controls. This systemic oxidative stress was associated with fibrinogen oxidation with fibrinogen structural alterations. Thrombin-catalyzed fibrin polymerization and fibrin resistance to plasmin-induced lysis were significantly altered in patients compared with controls. Moreover, steatotic graft and smoking habit were associated with high fibrin degradation rate.</p></div><div><h3>Conclusion</h3><p>ROS-induced fibrinogen structural changes might increase the risk of thrombosis in liver transplant recipients.</p></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2475037924002504/pdfft?md5=35fdaba75960d81f8bd6a4437c8506af&pid=1-s2.0-S2475037924002504-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142167780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prescription and switching patterns of direct oral anticoagulants in patients with atrial fibrillation","authors":"","doi":"10.1016/j.rpth.2024.102544","DOIUrl":"10.1016/j.rpth.2024.102544","url":null,"abstract":"<div><h3>Background</h3><p>The patterns of direct oral anticoagulant (DOAC) selection and switching to a different oral anticoagulant (OAC) in patients with atrial fibrillation (AF) are unknown.</p></div><div><h3>Objectives</h3><p>To describe temporal patterns in first DOAC prescriptions, estimate the incidence, and identify predictors of switching to a different OAC within 1 year in OAC-naive AF patients.</p></div><div><h3>Methods</h3><p>In this retrospective cohort study, using a near-nationwide prescription registry (IQVIA, the Netherlands), we determined the number of patients per month initiated on each DOAC and identified predictors of switching within 1 year with robust Poisson regression.</p></div><div><h3>Results</h3><p>We included 94,874 patients. From November 2015 to November 2019, the monthly use of apixaban (<em>n</em> = 366 to <em>n</em> = 1066, +191%), rivaroxaban (<em>n</em> = 379 to <em>n</em> = 868, +129%), and edoxaban (<em>n</em> = 2 to <em>n</em> = 305, +15,150%) increased, whereas that of dabigatran decreased (<em>n</em> = 317 to <em>n</em> = 179, −44%). In the 66,090 patients with ≥1 year of available calendar time, 7% switched to a different OAC within 1 year. Strong predictors of switching to a different DOAC were using dabigatran (adjusted risk ratio [aRR], 3.33; 95% CI, 3.02-3.66) or edoxaban (aRR, 1.56; 95% CI, 1.34-1.82) rather than apixaban and using a standard DOAC dose (aRR, 2.54; 95% CI, 2.23-2.88). Strong predictors of switching to a vitamin K antagonist were using rivaroxaban (aRR, 1.36; 95% CI, 1.19-1.54 vs apixaban) and using a standard DOAC dose (aRR, 1.49; 95% CI, 1.26-1.77).</p></div><div><h3>Conclusion</h3><p>In the Netherlands, factor Xa inhibitors are increasingly being selected for OAC-naive AF patients. Seven percent of patients switch to a different OAC within 1 year, and the initial DOAC type and dose are strong predictors of switching.</p></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2475037924002395/pdfft?md5=3e676a8fe1eef5cad271dceb451f5210&pid=1-s2.0-S2475037924002395-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142129542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}